__timestamp | Exelixis, Inc. | Mesoblast Limited |
---|---|---|
Wednesday, January 1, 2014 | 189101000 | 55305000 |
Thursday, January 1, 2015 | 96351000 | 77593000 |
Friday, January 1, 2016 | 95967000 | 50013000 |
Sunday, January 1, 2017 | 112171000 | 58914000 |
Monday, January 1, 2018 | 182257000 | 65927000 |
Tuesday, January 1, 2019 | 336964000 | 59815000 |
Wednesday, January 1, 2020 | 547851000 | 56188000 |
Friday, January 1, 2021 | 693716000 | 53012000 |
Saturday, January 1, 2022 | 891813000 | 32815000 |
Sunday, January 1, 2023 | 1044071000 | 27189000 |
Monday, January 1, 2024 | 910408000 | 25353000 |
In pursuit of knowledge
In the competitive world of biotechnology, innovation is the key to success. Exelixis, Inc. and Mesoblast Limited are two companies that have consistently invested in research and development (R&D) to drive their growth. Over the past decade, Exelixis has significantly outpaced Mesoblast in R&D spending, with a staggering 1,000% increase from 2014 to 2023. In 2023 alone, Exelixis allocated over 90% more to R&D than Mesoblast, highlighting its commitment to innovation.
Mesoblast, while investing steadily, has seen a more modest increase in R&D expenses, with a peak in 2015. The data suggests that Exelixis's aggressive investment strategy may be positioning it as a leader in the biotech sector. As we look to the future, the question remains: will Mesoblast ramp up its R&D efforts to compete with Exelixis's innovation-driven approach?
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Exelixis, Inc.
R&D Insights: How Novartis AG and Exelixis, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Exelixis, Inc.
Research and Development Investment: Insmed Incorporated vs Exelixis, Inc.
Research and Development Investment: Dr. Reddy's Laboratories Limited vs Mesoblast Limited
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Revenue Insights: Exelixis, Inc. and Mesoblast Limited Performance Compared
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Exelixis, Inc. vs Wave Life Sciences Ltd.
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.